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Thrombolysis remains the only beneficial therapy for ischemic stroke, but is restricted
to a short therapeutic window following the infarct. Currently research is focusing
on spontaneous regenerative processes during the sub-acute and chronic phase.
Angiogenesis, the formation of new blood vessels from pre-existing ones, was observed in
stroke patients, correlates with longer survival and positively affects the formation of new
neurons. Angiogenesis takes place in the border zones of the infarct, but further insight
into the temporal profile is needed to fully apprehend its therapeutic potential and its
relevance for neurogenesis and functional recovery. Angiogenesis is a multistep process,
involving extracellular matrix degradation, endothelial cell proliferation, and, finally, new
vessel formation. Interaction between vascular endothelial growth factor and its receptor
2 (VEGFR2) plays a central role in these angiogenic signaling cascades. In the present study
we investigated non-invasively the dynamics of VEGFR2 expression following cerebral
ischemia in a mouse model of middle cerebral artery occlusion (MCAO). We used a
transgenic mouse expressing firefly luciferase under the control of the VEGFR2 promotor
to non-invasively elucidate the temporal profile of VEGFR2 expression after stroke as a
biomarker for VEGF/VEGFR2 signaling. We measured each animal repetitively up to 2
weeks after stroke and found increased VEGFR2 expression starting 3 days after the
insult with peak values at 7 days. These were paralleled by increased VEGFR2 protein
levels and increased vascular volume in peri-infarct areas at 14 days after the infarct,
indicating that signaling via VEGFR2 leads to successful vascular remodeling. This study
describes VEGFR2-related signaling is active at least up to 2 weeks after the infarct and
results in increased vascular volume. Further, this study presents a novel strategy for the
non-invasive evaluation of angiogenesis-based therapies.
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INTRODUCTION
Angiogenesis, the formation of new blood vessels from pre-
existing ones, is recognized as a potential new therapeutic
target in ischemic stroke (Slevin et al., 2006; Navaratna et al.,
2009; Shibuya, 2009). Increased vascularization in areas sur-
rounding the infarct has been observed in human (Krupinski
et al., 1994; Szpak et al., 1999) as well as in animal brain
tissue (Beck et al., 2000; Marti et al., 2000; Hayashi et al.,
2003; Thored et al., 2007; Li et al., 2011) and is associated
with improved functionality (Krupinski et al., 1994; Wang
et al., 2006; Lee et al., 2007b; Reitmeir et al., 2012). Further-
more, angiogenesis is closely linked to neurogenesis and has
shown positive effects on neuronal cell formation, migration
and maturation (Taguchi et al., 2004). These results support
the hypothesis, that angiogenesis after stroke is therapeutically
advantageous.
The absence of adequate blood supply caused by the blockage
of a cerebral artery leads to tissue hypoxia, which triggers the
angiogenic response (Marti et al., 2000; Beck and Plate, 2009).
Hypoxia inducible factor (HIF) 1α is stabilized under hypoxic
conditions and dimerizes with HIF1β to form a transcription
factor, which binds to the hypoxia responsible element in the pro-
motor region of several hypoxia inducible cytokines and growth
factors (Ferrara et al., 2003; Hayashi et al., 2006). The most
potent angiogenic factor is the vascular endothelial growth factor
(VEGF), which exerts its effect through its main receptor, i.e.,
vascular endothelial growth factor receptor 2 (VEGFR2; Ferrara
et al., 2003; Koch et al., 2011). Activation of the VEGFR2 results
in endothelial cell proliferation, migration and differentiation
(Ferrara et al., 2003; Hayashi et al., 2006). Therefore, VEGFR2
plays a key role in adult angiogenesis and represents a molec-
ular biomarker for angiogenic signaling in tissue. In a mouse
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model of middle cerebral artery occlusion (MCAO), VEGFR2
was upregulated as early as 1 h poststroke, continued to increase
for up to 1 week and decreased thereafter (Marti et al., 2000;
Hayashi et al., 2003; Cai et al., 2009). Poststroke VEGFR2 expres-
sion was observed in neuronal and endothelial cells—neuronal
VEGFR2 expression was early and transient, while its expression
on endothelial cells persisted for prolonged time after the ischemic
insult (Hayashi et al., 2003). Although poststroke VEGFR2 induc-
tion is not restricted to endothelial cells, its sub-acute and chronic
expression is pre-dominently on endothelial cells. Furthermore,
poststroke angiogenesis is VEGF/VEGFR2 signaling dependent, as
inhibition of the VEGFR2 receptor resulted in decreased vascular
regeneration and reduced regional cerebral blood flow (Li et al.,
2011). The time profile of VEGFR2 expression after stroke is
mainly based upon invasive methods like immunohistochemistry
(IHC), Western blot (WB) and mRNA analysis. Up to date,
only one study approached the non-invasive tracking of VEGFR2
expression as a correlate for angiogenesis after stroke (Cai et al.,
2009). Using a PET-tracer for VEGF receptors Cai et al. (2009)
found increased VEGFR2 expression in the ischemic hemisphere
of rats until 16 days after stroke, and it subsequently decreased to
almost normal levels at 23 days post-stroke. However, the tracer
detected both, VEGFR2 and VEGFR1.
In the following study we utilized the VEGFR2 as a biomarker
for the molecular regulation of angiogenic remodeling after
stroke. We used the non-invasive imaging technique of biolumi-
nescence to monitor the dynamic changes in VEGFR2 expres-
sion in a VEGFR2-luc reporter mouse with VEGFR2-specific
photon emission (PE). We observed the temporal dynamics
of VEGFR2 expression up to 2 weeks after stroke and vali-
dated the elevated VEGFR2 levels in the ischemic hemisphere
by Western blotting of the receptor. Subsequently we evaluated
the effect of increased VEGFR2 expression on vessel density by
quantifying changes in vascular volume on immunohistological
sections.
MATERIALS AND METHODS
ANIMAL MODEL
All animal experiments were conducted according to the guide-
lines laid out in the German Animal Welfare Act, in accor-
dance with the European Council Directive 2010/63/EU, and
were approved by the Landesamt für Natur, Umwelt und
Verbraucherschutz North Rhine-Westphalia, reference number
84-02.04.2011.A123, as well as by the bioethics committee from
Leiden University Medical Center, Leiden, The Netherlands, refer-
ence number 10215. A transgenic knock-in mouse model (Lyons
et al., 2005) which expresses firefly luciferase under the con-
trol of the VEGFR2 promotor was used for all experiments.
The animals were kept under ad libitum supply of food and
water in a 12 h/12 h day and night cycle. All measurements
and surgical interventions were performed under isoflurane
anesthesia.
EXPERIMENTAL GROUPS
In total 39 male VEGFR2-luc knock-in mice (7–13 weeks old)
were randomly assigned into groups of different survival times
and different post mortem tissue processing. Six healthy control
FIGURE 1 | Study design and group sizes. (A) Sham and MCAO animals
were measured before (pre), and 3, 7, 14 days (3d, 7d, 14d) after 30 min
MCAO with MRI and BLI. At 7d and 14d post MCAO tissue was collected
for WB and IHC. (B) The displayed final group sizes as used per method and
group. Excluded animals are not listed. (MCAO: middle cerebral artery
occlusion, MRI: magnetic resonance imaging, BLI: bioluminescence
imaging, WB: western blot, IHC: immunohistochemistry).
animals were measured with bioluminescence at three different
days for the assessment of inter- and intra-animal stability of
bioluminescence kinetics from the brain. Twelve animals received
a sham surgery of which three had to be excluded due to death
(n = 1) and spontaneous hyperintense brain areas on T2-weighted
MR images (n = 2). Eighteen mice received a 30 min occlusion of
the right middle cerebral artery of which two were excluded due to
lack of stroke (n = 1) and strong weight loss (n = 1). Middle cere-
bral artery occlusion and sham animals were imaged 3 to 7 days
before surgery (baseline acquisition) and 3, 7 and 14 days post
surgery. Each bioluminescence imaging (BLI) session was directly
followed by a magnetic resonance imaging (MRI) acquisition of
T2 maps. Between day 3 and day 7 post surgery, sham and stroke
animals received injections of 5-bromo-2′-deoxyuridine (BrdU,
Sigma Aldrich, Taufkirchen, Germany) twice daily (50 mg/kg). At
the end time point brain tissue was collected for either Western
blots or IHC. An overview of the study design and final group
sizes is presented in Figure 1.
MIDDLE CEREBRAL ARTERY OCCLUSION
The ischemic lesion was induced by transient occlusion of the
right middle cerebral artery (MCAO), using the intraluminal
filament model adapted from rat. The specific surgical method
used in this study equals previously described MCAO in mice
(Bahmani et al., 2011). Mice were anesthetized with 1–2% isoflu-
rane in a 30/70 oxygen/air mixture and received a subcutaneous
injection of 4 mg/kg buprenorphin (Temgesic, Merck, Darmstadt,
Germany) for analgesia. A neck incision exposed the common
carotid artery (CCA) and a silicon rubber-coated filament with
a tip diameter of 170 µm (7017PK5Re, Doccol Corporation,
Sharon, MA USA) was introduced into its lumen. The filament
was advanced through the internal carotid artery (ICA) until it
blocked the blood flow to the middle cerebral artery. Animals
were allowed to recover under a red light lamp during the
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occlusion period. After 30 min of occlusion, animals were re-
anesthetized and reperfusion was initiated by filament removal.
The CCA was permanently ligated. Sham surgery involved the
partial introduction of a filament into the CCA without blocking
the blood flow to the MCA. Animals were also recovered for
30 min and re-anesthetized for filament removal. The CCA was
also ligated permanently. Following MCAO surgery, all animals
received s.c. injections of 1 ml NaCl twice daily until the body
weight stabilized.
BIOLUMINESCENCE IMAGING
One day prior to the first BLI session, mice were anesthetized in
2% isoflurane and the fur on the head was shaved to allow better
photon penetration. It was not necessary to shave the animals
a second time during the study. Photon emission was captured
using the IVIS 100 (Perkin-Elmer, Waltham, MA, USA) equipped
with a mirror system (prototype, Perkin-Elmer) consisting of two
mirrors at a 45◦ angle to the basis (Figure 2A). Mice were indi-
vidually anesthetized in 2% isoflurane and subsequently injected
i.p. with 150 mg/kg click beetle luciferin (Promega, Madison,
WI, USA) (stock solution 20 mg/ml). The acquisition of PE was
directly started after luciferin injection with Living Image software
(binning = 4, aperture = 1; Perkin-Elmer). Fifteen consecutive
measurements of 1 min duration were performed in order to
capture the inflow kinetics. Photon emission was analyzed for
different regions of interest (ROIs; Figure 2A). Regions of interest
were kept constant in size and were positioned on the photo-
graphic image using anatomical landmarks for guidance (ears,
eyes; compare Figure 2A). Inflow kinetics and PE of the 15th min
(PE15) after injection were extracted for each ROI. PE15 values
from the “ischemic hemisphere” ROI and the “mirror ischemic”
ROI were subsequently divided by the “intact hemisphere” and
“mirror intact” ROI, respectively, in order to receive a quantitative
ratio of change relative to the intact hemisphere. All values are
displayed as mean± standard deviation.
MAGNETIC RESONANCE IMAGING
Experiments were performed on a 7 Tesla Bruker Pharmas-
can 70/16 (Bruker Biospin, Ettlingen, Germany) with a 16 cm
horizontal bore magnet and a 9 cm (inner diameter) shielded
gradient, a maximum gradient strength of 300 mT/m, and
a 23-mm birdcage transmit-receive RF coil (Bruker Biospin,
Ettlingen, Germany). A multi-slice multi-echo (MSME) sequence
(TR/TE = 4000 ms /11 ms, 16 echoes, 8 slices, slice thick-
ness 1 mm, FOV 1.5 × 1.5 cm, matrix 128 × 128, resolution
117× 117 µm) was measured for T2 evaluation and visualization
of lesion location. T2 maps were calculated with IDL software
(Exelis Visual Information Soution, Boulder, CO, USA).
WESTERN BLOTTING
Animals were deeply anesthetized and killed by cervical dis-
location. Brains were removed quickly and placed in ice cold
phosphate buffered saline (PBS). Left and right cortex, as well as
left and right striatum were dissected and directly frozen on dried
ice. Tissue was stored at −80◦C until further processing. Tissue
was lysated in cell lysis buffer (#9803, Cell signaling Technology,
Beverly, MA, USA) and treated with protease inhibitor complete
FIGURE 2 | Assessment of brain kinetics and stability of the BLI signal
from healthy animals. (A) Animals were placed in a prone position on an
elevated bar between two 45◦ mirrors. BLI was evaluated in four different
regions of interest: ipsi- and contralateral top view, ipsi- and contra-lateral
mirror (side) view. (B) Measuring PE directly after luciferin injection reveals
brain specific inflow kinetics. An inflow phase between 1–10 min can be
distinguished from a plateau phase of maximal PE between 12 and 15 min
after injection. Emission from ipsi- and contralateral hemisphere was
consistently of same magnitude. (C) Healthy control animals were
measured repetitively for the assessment of the inter- and intra-animal
variability of the BLI signal. MRI and BLI images of an exemplary healthy
animal show an intact brain and stable intensity of PE over time. MRI is
shown as coronal brain section, BLI is shown as horizontal planar projection
of the PE onto the mouse photograph. (D) Three-fold measurement of each
healthy animal revealed intra-individual variability of 3–30%. Inter-animal
variability was around 20% to 45%. (E) Normalization of PE from ipsi- to
contralateral hemisphere eliminates intra- and inter-animal variability and
results in stable bioluminescence over time. Data is presented as mean ±
standard deviation. (PE: photon emission, PE15: photon emission of the
15th minute after luciferin injection).
Mini (CatNo 04693159001, Roche Applied Science, Indianapolis,
Indiana, USA) supplemented with phenylmethylsulphonyl fluo-
ride (PMSF, P6726, Sigma-Aldrich, Taufkirchen, Germany). Pro-
tein concentration was determined using the BCA Protein Assay
Kit (Pierce, Rockford, IL, USA). For each sample equal amounts
of protein were electrophoresed through 8–16% SDS–PAGE
gel (Invitrogen, Life Technologies, Darmstadt, Germany) and
subsequently electrotransferred to nitrocellulose membranes
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(ProTran, Whatman, Kent, UK). Membranes were probed with
the primary antibodies for VEGFR2 (1:500; #2479, Cell Signal-
ing Technology, Beverly, MA, USA), and β-actin (1:5000; MP
Biomedical, Solon, Ohio, USA) overnight at 4◦C. For detec-
tion, horseradish peroxidase-conjugated secondary antibodies
were used (1:3000 for β-actin, 1:800 for VEGFR2) followed by
enhanced chemiluminescence development with Amersham ECL
Western Blotting Detection Reagents (GE Healthcare, Bucking-
hamshire, UK). Results were analyzed using ImageJ software1
(NIH). Regions of interest with constant size were positioned
over each protein band and the integrated density was quan-
tified followed by background subtraction and normalization
to the β-actin signal. Data from the ischemic/sham hemisphere
was then normalized to the intact hemisphere and displayed as
mean± standard deviation.
IMMUNOHISTOCHEMISTRY
Animals were deeply anesthetized and transcardially perfused
with ice cold PBS followed by 20 ml 4% paraformaldehyde.
Subsequently, brains were removed and shock frozen in −40◦C
methylbutane (Sigma-Aldrich, Taufkirchen, Germany). Brain tis-
sue was stored at −80◦C until further processing. Brain sections
of 10 µm thickness were cut on the cryostat (Leica Microsys-
tems, Wetzlar, Germany) and stored at −20◦C. Sections for BrdU
staining were pretreated with 2N hydrochloric acid for 2 h at
room temperature. Prior to immunostaining, sections were pre-
incubated at room temperature in 5% normal serum and 0.25%
Triton X-100, in KPBS for 45 min. Primary antibodies were incu-
bated overnight at 4◦C. The following primary antibodies were
used for double staining: anti-laminin (1:100, ab11575, Abcam,
Cambridge, UK), anti-GFAP (1:200, G3898, Abcam Cambridge,
UK), biotinylated Solanum tuberosum (potato) lectin (1:100, B-
1165, Vector Laboratories, Burlingame, CA, USA), anti-BrdU
(1:100, ab6326, Abcam, Cambridge, UK). Secondary antibodies
were applied for 2 h at room temperature. A biotin-conjugated
secondary antibody (1:200, Vector Laboratories, Burlingame,
USA) was used with Alexa 488-conjugated streptavidin (1:200,
Molecular Probes, Invitrogen, Life Technologies, Darmstadt, Ger-
many). Cy2 and Cy3 (1:200, Jackson Immuno Research, West
Grove, PA, USA) were used as complementary secondary antibod-
ies for double staining, and Hoechst 33342 (1:1000 Invitrogen,
Carlsbad, USA) was added during final incubation with sec-
ondary antibodies for nuclear staining. Slides were coverslipped
with mounting medium (Entellan, Merck, Darmstadt, Germany).
Z-stacks of BrdU/lectin positive cells were acquired with a con-
focal microscope (Leica TCS SP8, Leica Microsystems, Wetzlar,
Germany). Laminin/GFAP double staining was used for vascular
volume estimation. Microscopic images of whole brain sections
were acquired at 4×magnification with a fluorescent microscope
(BZ-9000 Keyence, Osaka, Japan). Areas of interest were defined
inside the glial scar (“cortex core”, “striatum core”) and outside
the glial scar (“cortex peri”, “striatum peri”). From each area of
interest three images were taken at 20× magnification from the
ischemic side and from corresponding homotopic areas within
the intact hemisphere, while holding exposure time constant.
1http://rsbweb.nih.gov/ij/
Using the Keyence microscope processing software, the area of
staining was quantified in these ROIs by fixed thresholding and
constant cut-off of clusters of small size (<100 pixels), which were
regarded as unspecific dirt and were eliminated from the selec-
tion. Subsequently, the area covered by the staining was calculated
for each image and a ratio was made to the corresponding image
of the intact hemisphere. This procedure was chosen to con-
servatively control for differences in staining intensities between
animal sections, although the staining was highly reproducible
and in particular even across sections. A mean was calculated for
each region for each animal. Subsequently, a group mean was
calculated for each region. Data is presented as group mean ±
standard deviation.
STATISTICS
Statistical analysis was performed with SPSS version 15 (IBM
SPSS statistics, Ehningen, Germany). In vivo BLI data was tested
for significant changes using a repeated measures analysis of
variance (RM-ANOVA) with Bonferroni corrected post hoc com-
parisons. Western blot data was tested for significant changes
by one way analysis of variance (one way ANOVA) with least
significant difference post hoc comparisons between groups. Using
an independent one-tailed Student’s t-test we tested vascular
volume for significant changes between the stroke and the sham
group. We performed bivariate correlation analysis between bio-
luminescence and Western blot data as well as between biolumi-
nescence and vascular volume data with Spearman’s ρ correlation
coefficient. A p-value ≤ 0.05 was considered to be statistically
significant.
RESULTS
INTER- AND INTRA-ANIMAL STABILITY AND KINETICS OF THE
BIOLUMINESCENCE SIGNAL
We characterized the PE kinetics from the brain of six healthy
transgenic mice expressing firefly luciferase under the control of
the VEGFR2 promotor using the ROIs depicted in Figure 2A. All
animals showed increasing PE from the brain between 1 to 10 min
after luciferin injection. Photon emission reached a maximum
between 10 and 13 min and remained on this level in a plateau
phase until the end of the measurement at 15 min post injection
(Figure 2B). Photon emission kinetics and intensity from the
right (ipsilateral) hemisphere were equal to the left (contralateral)
hemisphere for each individual animal (Figure 2B). We therefore
continued to evaluate the PE of the 15th minute after luciferin
injection (PE15), which represents maximum PE. Healthy animals
were measured at three consecutive days for the assessment of
inter- and intra-animal stability. Repetitive MRI on the healthy
subjects reveals stable T2 values between time points and equal-
ity of both hemispheres. Corresponding BLI of this exemplary
animal, presented as color-coded PE15, confirms reproducibly
equal VEGFR2 baseline expression in both hemispheres, as well
as a stable PE15 over time (Figure 2C). Nevertheless, repeated
measurement of the same animal resulted in PE15 variations from
3 to 30% of the mean and absolute signal intensity variation
between animals was between 20 to 45% of the mean (Figure 2D).
In order to investigate BLI changes over time, we corrected for
inter- and intra-individual variation by normalizing the ischemic
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FIGURE 3 | Qualitative and quantitative evaluation of BLI changes after
sham and MCAO surgery. (A) Representative longitudinal MRI and BLI data
set from one animal that received MCAO surgery. MRI is shown as coronal
brain section, BLI is shown as horizontal planar projection of the PE onto the
mouse photograph. After MCAO, a clear lesion is visible in the right
hemisphere on T2 maps. BLI signal intensity starts to increase 3d post-stroke
and PE is clearly increased over the ischemic hemisphere compared to the
intact hemisphere at 7d and 14d post-stroke. Increased PE from the ischemic
hemisphere is distinctively visualized in the mirrors. (B) Representative
longitudinal MRI and BLI data set from one animal that received sham
surgery. Sham surgery did not result in lesion formation confirmed by
unchanged T2 maps. However, sham surgery lead to a transient increase in
PE from the ipsilateral side, which was best visible in the mirror system. (C)
BLI kinetics of the ischemic and the intact hemisphere at 14d post sham
surgery (upper graph) and MCAO surgery (lower graph). (D) Quantification of
BLI changes was achieved by normalization of PE from ipsi- to contralateral
hemisphere for the top view (left graph) and the mirror view (right graph).
Pre-stroke PE was consistently equal in all investigated groups with a
stronger variation in the mirror view. Increased PE was significantly different
to pre-stroke values on day three for stroke, but also for sham animals in both
views. At 7d and 14d, elevated PE in stroke animals was statistically
significant compared to pre-stroke values (both p < 0.001) and to the sham
group (p = 0.001, p = 0.004). (black = stroke, gray = sham, * p < 0.05,
** p < 0.01, *** p < 0.001; # comparison between groups p < 0.01).
(ipsilateral) to the intact (contralateral) hemisphere. This anal-
ysis strategy shows stable equal VEGFR2 expression in healthy
subjects over time (Figure 2E), thus allowing for reproducible
and stable assessment of the hemispheric differences in VEGFR2
expression.
CEREBRAL ISCHEMIA
Cerebral ischemia was induced by 30 min occlusion of the right
MCA with a silicone rubber-coated filament. Lesion size, location
and development were assessed by MRI using quantitative T2
maps. Lesions appear as areas of increased T2 values on T2 maps,
and a representative lesion is displayed in Figure 3A. Lesions were
of similar size throughout all groups, including damage in the
striatum and the parietal cortex, except for one animal of the 7d
IHC group that showed only a small striatal infarct. At 14 days
after MCAO, the ischemic hemisphere has shrunken in size, giving
space to cerebrospinal fluid, which is visible as a rim of increased
T2 value along the ischemic cortex.
BIOLUMINESCENCE OF VEGFR2 EXPRESSION AFTER STROKE
Before MCAO, T2 maps displayed no signs of lesion and PE
was comparable for the right and left hemisphere (Figure 3A,
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first row). Three days after MCAO, vasogenic edema resulted in
increased T2 values, and a clear lesion was visible in the right
hemisphere on T2 maps (Figure 3A, second row). Middle cerebral
artery occlusion induced a significant increase in PE from the
ischemic hemisphere (top view: F(1.8,33.7) = 14.8, p < 0.001;
mirror view: F(3,45) = 12.224, p < 0.001). Photon emission from
the ischemic hemisphere was already significantly increased at
3 days post MCAO compared to pre stroke values (top view:
p= 0.002, mirror view: p= 0.006) indicating an early upregulation
of VEGFR2 expression. Photon emission continued to increase
from the ischemic hemisphere and was clearly visible on BL
images on 7d and 14d after MCAO. The maximal PE increase of
58± 36% (p =< 0.001) in the ischemic hemisphere was observed
7d post MCAO in the top view (Figure 3D, left graph). The PE
increase was even more pronounced (78± 26%; p< 0.001) when
observed through the mirror system (Figure 3D, right graph).
At the last observation time point of 14d post MCAO, the PE
was still strongly increased in the ischemic hemisphere in both,
the top view (44 ± 34%; p = 0.001) and the mirror view (65 ±
26%; p = 0.001). The pathological condition of ischemia does not
alter the BLI kinetics described for healthy control mice. Photon
emission from the ischemic hemisphere reaches the plateau phase
also between 10–13 min but with higher PE than from the intact
hemisphere (Figure 3C).
Sham surgery (introduction of the filament into the ICA but
without advancing it to occlude the MCA) did not result in
lesion formation (cf. T2 maps in Figure 3B), but, nevertheless,
resulted in a transient change in PE on the ispilateral hemisphere
(Figures 3B,D) at 3 days after surgery (top view: 15 ± 18%
p= 0.019; mirror view: 58± 31% p= 0.026). The increase in emis-
sion was of similar magnitude as observed in the MCAO group.
Although emission from the sham hemisphere stayed elevated at
7d and 14d, the change to the pre-surgery values was no longer
significant (Figure 3D). The upregulation of VEGFR2 expression
was significantly higher in MCAO animals when compared to
sham animals (F(1.77,33.67) = 10.19 p = 0.001) at 7d (p = 0.001)
and at 14d (p = 0.004).
WESTERN BLOT ANALYSIS
Western blot analysis of healthy control animals shows little
change in VEGFR2 expression between left and right hemisphere.
Middle cerebral artery occlusion results in changes in VEGFR2
protein content of the ischemic hemisphere (Figures 4A,B). Sig-
nificantly elevated levels of VEGFR2 protein were found in the
ischemic cortex (40 ± 21%, p = 0.005) and in the ischemic
striatum (32 ± 43%, p = 0.048) compared to healthy control
animals (Figure 4C). Sham surgery resulted in non-significant
elevation of VEGFR2 protein in the cortex (20 ± 15%), but an
apparent decrease in the striatum (−7± 20%; Figure 4C).
IMMUNOHISTOCHEMISTRY
Histology was performed on the brains to determine changes in
vascular volume after MCAO. 10-µm-thick brain sections were
therefore stained with laminin. The stained area was interpreted
as vascular volume. Glial fibrillary acidic protein staining was used
for characterization of astrocyte activation in association with the
ischemic lesion. Overview images were acquired for identification
of the four areas of interest: the core lesion in the cortex (cortex
core), the peri-infarct area of the cortical lesion (cortex peri),
the striatal core lesion (striatum core), and the peri-infarct area
of the striatal lesion (striatum peri). Three close-ups of 20×
magnification were taken from each area of interest and from
corresponding sites of the intact hemisphere with equal exposure
times. Figure 5A shows representative close-ups of each region.
As a measure for vascular volume changes, the area positive for
laminin was compared between the ischemic hemisphere and the
corresponding regions on the contralateral hemisphere (% area,
normalized to contralateral side). Vascular volume was strongly
reduced in the cortical core region in MCAO animals at 14 days
after stroke (34± 17%, p = 0.08), but not in the striatal core. Peri-
infarct regions of both, cortex and striatum, showed increased
vascular volume, reaching significance in the striatum (29± 23%,
p = 0.03; Figure 5B). Sham animals did not differ from healthy
animals in all investigated brain regions. In each region that
showed increased vascular volume, we observed endothelial cells
with incorporated BrdU (Figures 5C–E), indicating that angio-
genic signaling resulted in endothelial cell proliferation during
day 3 and 7 after MCAO.
CORRELATION OF BIOLUMINESCENCE INTENSITY WITH PROTEIN
EXPRESSION AND VASCULAR VOLUME
Middle cerebral artery occlusion resulted in an increase in bio-
luminescene intensity from the ischemic hemisphere, which was
paralleled by the observation of increased VEGFR2 protein con-
tent and increased vascular volume. For the completeness of this
study we performed correlation analysis of the bioluminescence
signal intensity with VEGFR2 protein content on the one side,
or with vascular volume on the other side (Figure 6). Biolumi-
nescence intensity correlates well with VEGFR2 protein content
in the cortex (ρ = 0.474, p = 0.44). No correlation was found
between bioluminescence and protein content in the striatum,
which is due to the stronger absorption of photons from this
deeper structure. Therefore signal from the striatum will be
overlayed by signal from the cortex. Also a significant correlation
was observed to vascular volume in peri-infarct areas (ρ = 0.817,
p< 001).
DISCUSSION
We non-invasively observed the temporal profile of VEGFR2
expression after cerebral ischemia as a molecular reporter for
post-stroke pro-angiogenic signaling, while we followed lesion
development with the complementary method of MRI. VEGFR2
plays a key role in post-ischemic vascular remodeling and we
found increased expression lasting up to 14d post MCAO, which
was paralleled by an increased vascular volume in distinct peri-
infarct areas.
METHODOLOGICAL CONSIDERATIONS
Bioluminescence imaging is a very sensitive method and allows
for the detection of even small changes in cell numbers (Keyaerts
et al., 2008). However, it has a poor spatial resolution. For
the first time we report here the additional observation of PE
through two 45◦ angled mirrors for a better discrimination of
left and right hemisphere through lateral views. Signal changes
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FIGURE 4 | Qualitative and quantitative evaluation of tissue VEGFR2
protein content. (A) Representative Western blots from cortical tissue
samples for each group showing increased VEGFR2 (210 and 230 kDa)
content in the ischemic cortex of animals that underwent MCAO. Note
the strong increase in the 7d group. Sham animals and healthy control
display similar levels between left and right hemisphere. (B)
Representative Western blots from striatal tissue samples. Strongest
elevation is visible in the 14d MCAO group. (C) Semi-quantification
(including normalization to actin) and subsequent normalization to the
intact hemisphere reveals significant increased VEGFR2 expression in the
ischemic cortex (p = 0.005) and ischemic striatum (p = 0.048) (* p < 0.05,
** p < 0.01).
were consistently greater with intensity readouts from the mirror
views, but variation of the signal was also increased, suggesting
the introduction of additional noise. In vitro, a linear corre-
lation exists between PE and number of luciferase expressing
cells. In vivo this relation is affected by luciferin distribution
and photon absorption and scattering by tissue (Virostko et al.,
2004; Inoue et al., 2009; Keyaerts et al., 2011). Bioluminence
imaging of the brain has to deal with limited substrate diffusibility
through the blood brain-barrier (BBB; Berger et al., 2008). Brain
pathologies, which result in a breakdown of the BBB, impose
even further methodological obstacles towards the interpretation
of the PE. Theoretically, an open BBB may facilitate luciferin
inflow on the ischemic hemisphere, thus resulting in higher PE
due to higher substrate availability, possibly mistaken for higher
luciferase content. However, we can exclude the open BBB as
dominating confounding factor in this animal model and study,
since sham animals with intact BBB have PE increase equal to
MCAO animals with open BBB at 3d post surgery. If carotid
artery occlusion (sham surgery) disturbs the BBB integrity, it
will be of much less intensity than by stroke. Hence, if the
increase at that time point was only due to increased luciferin
content rather than increased expression of VEGFR2 (and there-
fore luciferase), then we should have had observed stronger
signal in MCAO compared to sham. Furthermore, increased
wash-in of luciferin due to an open BBB would result in faster
slopes of the signal kinetics. This, however, was not seen at all.
We can therefore safely conclude that BBB breakdown in this
model does not affect the bioluminescence reaction and that the
increase in PE can be solely attributed to increased VEGFR2
expression.
VEGFR2 UPREGULATION DURING POST-STROKE ANGIOGENESIS
In order to non-invasively monitor VEGFR2 expression following
stroke, we made use of a transgenic mouse expressing luciferase
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FIGURE 5 | Immunohistochemical analysis of vascular changes. (A)
Immunohistochemistry of laminin for vascular volume estimation.
Representative close-ups of 20x magnification for each region of interest
visualize changes in vessel density. (B) Quantification and subsequent
normalization to the intact hemisphere confirms decreased vascular volume
in the core region of the cortex but not in the core region of the striatum.
Vascular volume increases significantly in the striatal peri-infarct zone (p =
0.03) but does not reach significance in peri-infarct cortex (p = 0.08). Sham
animals showed little changes in corresponding areas of the brain. (C–E)
Three examples of Z-stacks of representative BrdU+/lectin+newly formed
endothelial cells from the peri-infarct striatum (C) and the cortex (D,E). Scale
bar 20 µm.
under the control of the VEGFR2 promotor (Lyons et al., 2005).
We observed increasing bioluminescence intensity after cerebral
ischemia in the ischemic hemisphere, which peaked at 7d post-
stroke. In agreement with previous reports (Marti et al., 2000;
Hayashi et al., 2003; Cai et al., 2009), our results show a continu-
ous increase in VEGFR2 expression from 3d to 7d post-stroke. We
observe still significantly elevated expression at 14d post-stroke,
which was confirmed by increased VEGFR2 protein content in the
ischemic hemisphere compared to the intact hemisphere. Semi-
quantitative analysis of regional VEGFR2 content in the brain by
Western blotting indicates strong expression in the ischemic stria-
tum and cortex, since the amount of VEGFR2 was increased by as
much as 40%. Also sham surgery resulted in a transient increase in
BLI signal from the sham hemisphere, indicating also upregulated
VEGFR2 expression. Western blot results show a slightly increased
VEGFR2 content at 14d post surgery in the right cortex, but
not in the striatum of sham animals. Sham surgery involved the
introduction of a filament only into the CCA. Upon removal of
the filament, the CCA was ligated permanently to control for
blood flow changes induced by the permanent ligation of the CCA
in the stroke group. Common carotid artery occlusion is used
as a model for mild hypoxia and chronic cerebral hypoperfusion
(Hecht et al., 2012; Pimentel-Coelho et al., 2012). Following the
occlusion of the ICA, Hecht et al. (2012) observed reduction by
80% in overall cerebral blood flow, while cortical perfusion was
not notably changed. Unilateral CCA occlusion did not result in
neuronal cell death within the territory of the MCAO (Pimentel-
Coelho et al., 2012), but at 21d after ICA occlusion, slightly
increased vessel density was noted in the ipsilateral cortex (Hecht
et al., 2012). Although our study did not indicate a strong increase
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FIGURE 6 | Correlations. (A) Changes of PE within the ischemic hemisphere correlates to VEGFR2 protein changes in the ischemic cortex (ρ = 0.474,
p = 0.044). (B) Photon emission increase also correlates to vascular volume changes within the ischemic hemisphere (ρ = 0.817, p < 0.001).
in cortical or striatal vascular volume, BLI was sensitive enough to
detect the minor changes in VEGFR2 expression induced by mild
hypoxia after CCA occlusion.
VASCULAR VOLUME INCREASE IN PERI-INFARCT AREAS
We investigated the vascular volume in core regions and in
peri-infarct regions of both, the cortex and the striatum. Our
MCAO model resulted in strong reduction in vascular volume
within the cortical core region. Similar observations were made
by Bosomtwi et al. (2011) in a distal MCAO rat model where
only the cortex is affected. Yet, in the region defined as striatum
core, we detected no decrease in vessel density. High upregulation
of VEGFR2 in the striatum, as indicated by our WB results,
may account for early enhanced endothelial survival due to
protective properties of VEGF2 (Ferrara, 2004; Shibuya, 2006;
Lee et al., 2007a; Hermann and Zechariah, 2009), and may even
have been followed by stabilization of existing or recruitment of
new vessels. In accordance with previous studies (Marti et al.,
2000; Hayashi et al., 2003; Thored et al., 2007; Li et al., 2011;
Reitmeir et al., 2012), we observed increased vascular volume
in the peri-infarct striatum (29 ± 23%) and peri-infarct cortex
(12% ± 17%). Vascular volume increase in the striatal peri-
infarct was most pronounced in the most dorsal part of the
striatum close to the subventricular zone (SVZ), which has been
described as highly angiogenic (Ohab et al., 2006; Thored et al.,
2007). Strong endothelial cell proliferation had been observed in
this area next to the SVZ between 1 and 2 weeks, and conse-
quently increased vessel density persisted up to 16 weeks (Thored
et al., 2007). Other studies reported endothelial cell proliferation
starting as early as 24 h after MCAO in mice (Hayashi et al.,
2003), and increased vessel density was detectable at 2–3d post-
stroke (Marti et al., 2000; Hayashi et al., 2003). The number
of microvessels remained increased up to 21d (Hayashi et al.,
2003). In both regions with increased vascular volume, striatal
and cortical peri-infarct, we detected proliferating endothelial
cells, which were newly generated in the first week after stroke,
due to BrdU incorporation. As new vessels can also form without
endothelial cell proliferation by splitting existing vessels through
the insertion of tissue pillars, intussusception (Adams and Alitalo,
2007) and peripheral bone marrow-derived endothelial progeni-
tor cells can contribute to vessel formation or stabilization (Zhang
et al., 2002) we restrained from quantification of BrdU positive
endothelial cells as this would underestimate the intensity of
increased vascular volume.
STROKE-INDUCED ANGIOGENIC SIGNALING CAN BE NON-INVASIVELY
QUANTIFIED WITH THE VEGFR2-luc MOUSE MODEL
The bioluminescence signal change reflected increased VEGFR2
expression within the ischemic hemisphere. Western blot anal-
ysis revealed increased VEGFR2 protein concentration in both,
ischemic striatum and cortex. In both regions, increased VEGFR2
expression translated into increased vascular volume. A posi-
tive correlation, not very strong but significant, between biolu-
minescence intensity and VEGFR2 protein content within the
cortex was observed and renders this mouse model an opti-
mal model for non-invasive tracking of VEGFR2 regulation in
the brain. No correlation was observed to VEGFR2 content of
the striatum. As BLI signal recorded by the CCD camera is
a two-dimensional image from the three-dimensional structure
of the brain, signals from deeper structures like the striatum
are subjected to stronger absorption by overlaying tissue than
signals from structures closer to the brain surface like the cor-
tex. Hence, the detected bioluminescence signal in this model
is strongly dominated by its contribution from cortex. A sig-
nificant correlation was also detected between PE intensity and
vascular volume. Such a correlation was not expected because
of the time delay between VEGFR2 expression and the occur-
rence of laminated microvessels, and due to additional expres-
sion of VEGFR2 by cells other than proliferating endothelial
cells (Hayashi et al., 2003). VEGFR2 is mainly expressed on
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endothelial cells and functions as transducer of survival, prolif-
eration, migration and differentiation cues (Ferrara et al., 2003).
Following stroke, the number of VEGFR2 positive endothelial
cells was strongly increased in the penumbra (Li et al., 2011),
but also post-ischemic neurons started to express this receptor
(Hayashi et al., 2003; Beck and Plate, 2009). However, neuronal
VEGFR2 expression was an early and transient effect, declining
already 3 days after ischemia, while its expression remained strong
in endothelial cells (Hayashi et al., 2003). Vascular endothelial
growth factor receptor 2 expression was also reported on astro-
cytes (Issa et al., 1999) and microglia/macrophages (Lennmyr
et al., 1998) following stroke, however, other groups could not
reproduce these results (Krum et al., 2002). Further, a distinct
pattern, where astrocytes express VEGFR1 and endothelial cells
express VEGFR2 was suggested (Krum et al., 2008). Therefore,
we believe it is justified to neglect the effect of neuronal and
glial poststroke VEGFR2 in our study. The changes in VEGFR2
levels we observe in the chronic phase after stroke represent
predominantly changes of VEGFR2 on endothelial cells. New
vessel formation is not restricted to on-site endothelial cell prolif-
eration but can occur also by intussusception (Adams and Alitalo,
2007) and by the contribution of peripheral bone marrow-derived
endothelial progenitor cells (Zhang et al., 2002). Also in these
processes signaling via the VEGFR2 plays a pivotal role. Poststroke
angiogenesis is VEGF/VEGFR2 signaling dependent, as selectively
blocking the VEGFR2 leads to decreased endothelial cell prolif-
eration and reduced cerebral blood flow (Li et al., 2011). We
can summarize that pro-angiogenic signaling via the VEGF—
VEGFR2 pathway is a general necessity for new vessel formation,
and non-invasive observation of the VEGFR2 expression pro-
vides longitudinal information about poststroke neurovascular
dynamics.
CONCLUSION
The present study established the value of the VEGFR2-luc mouse
model for non-invasive tracking of VEGFR2 expression as a
correlate for neurovascular remodeling in stroke pathology. We
have deciphered non-invasively and quantitatively a temporal
profile of VEGFR2 expression for the first 2 weeks after stroke.
Also, we have observed, that chronic VEGFR2 expression corre-
lates well with vascular volume increase in cortical peri-infarct
regions. Future studies will benefit from this newly validated
non-invasive tool for investigations of angiogenesis promoting
therapies.
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